

Edgar Filing: AVENTIS - Form 425

AVENTIS
Form 425
February 06, 2004

Filed by Sanofi-Synthelabo
Pursuant to Rule 135 and Rule 425(b) under the
United States Securities Act of 1933,
as amended, and deemed filed pursuant to Rule 14d-2(b)(2) of the
United States Securities Exchange Act of 1934, as amended

Subject Company: Aventis
Commission File No. 001-10378
Date: February 6, 2004

ON FEBRUARY 6, 2004, THE FOLLOWING ADVERTISEMENT WAS PUBLISHED ON
BEHALF OF SANOFI-SYNTHELABO IN BUSINESS WEEK EUROPEAN EDITION AND THE ECONOMIST
EUROPEAN EDITION.

* * * *

WE REFUSE TO ACCEPT THAT
THERE ISN'T A FASTER WAY TO FIND
A MEDICINE FOR TOMMY'S DISEASE.

[Image of child in hospital bed]

Who is going to tell Tommy that the medicine that could cure him won't be ready for 20 years? You? No. No one. Joining forces with Aventis will represent a giant step forward for research. We will be able to provide patients with new drugs and innovative solutions faster. Together, we will harness our complementary skills to create a leading pharmaceutical group (No.1 in Europe and No.3 worldwide) committed to improving healthcare and capable of driving strong, sustainable and profitable growth.

SANOFI-SYNTHELABO'S OFFER TO AVENTIS'S SHAREHOLDERS
BECAUSE HEALTH MATTERS

This advertisement does not constitute an offer to sell, or an offer to purchase, any securities

www.sanofi-synthelabo.com